Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction
JACC · 2025-08 · 86 (5) · 320-333
DOI: 10.1016/j.jacc.2025.05.033 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2025-08. Verfasst von João Pedro Ferreira und 27 weiteren Autor:innen. Beteiligte Einrichtung: RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal; Université de Lorraine, INSERM, Ce…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: AstraZeneca AG.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists improved heart failure outcomes in heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction; however, their combination was not tested in a randomized manner. Whether the SGLT2i/mineralocorticoid receptor antagonist combination offers benefits compared to SGLT2i alone requires dedicated trials. OBJECTIVES: This study aims to compare the efficacy and safety of dapagliflozin/spironolactone combination vs dapagliflozin alone in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction. METHODS: This was a prospective randomized open, blinded endpoint crossover trial. A sample size of 108 patients was powered to detect 0.15 Log N-terminal pro-B-type natriuretic peptide (NT-proBNP) difference between the dapagliflozin/spironolactone combination and dapagliflozin alone sequences study primary outcome. Each treatment sequence was given for 12 weeks. RESULTS: One hundred eight patients were randomized. The median age was 76 years (Q1-Q3: 71-81 years), 57% were women, estimated glomerular filtration rate (eGFR) 72 mL/min/1.73 m2 (Q1-Q3: 49-89 mL/min/1.73 m2), potassium 4.3 mmol/L (Q1-Q3: 4.0-4.6 mmol/L), and 45% had diabetes. The median NT-proBNP was 746 pg/mL (Q1-Q3: 401-1,493 pg/mL) and median LogNT-proBNP 6.6 Log-units (Q1-Q3: 6.0-7.3 Log-units). Compared to dapagliflozin, dapagliflozin/spironolactone combination reduced LogNT-proBNP levels: -0.11 (95% CI: -0.22 to -0.01) Log-units (P = 0.035) corresponding to an 11% relative reduction and increased the odds of reaching ≥20% NT-proBNP reduction (OR: 2.27; 95% CI: 1.16-4.44; P = 0.016). Compared to dapagliflozin, dapagliflozin/spironolactone combination reduced systolic blood pressure (-5.2 mm Hg; 95% CI: -8.4 to -2.0 mm Hg), reduced Logurinary-albumin-to-creatinine ratio (-0.32 Log; 95% CI: -0.54 to -0.11 Log) decreased eGFR (-6.4 mL/min/1.73 m2; 95% CI: -8.3 to -4.4 mL/min/1.73 m2), and increased serum potassium (+0.32 mmol/L; 95% CI: 0.23-0.41 mmol/L) and the frequency of serum potassium (>5.5 mmol/L: 5 [4.8%] vs 1 [0.9%]). CONCLUSIONS: Dapagliflozin/spironolactone combination reduced NT-proBNP more than dapagliflozin. A greater eGFR decline and potassium increase was observed with dapagliflozin/spironolactone combination (SOGALDI-PEF [Dapagliflozin With or Without Spironolactone for HFpEF]; NCT05676684).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal; Université de Lorraine, INSERM, Centre d'Investigations Cliniques, CHRU de Nancy, Inserm and INI-CRCT (C…
- RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal; Serviço de Medicina Interna, Unidade Local de Saúde São João, Porto, Portugal.
- RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
- Serviço de Medicina Interna, Unidade Local de Saúde São João, Porto, Portugal.
- Serviço de Cardiologia, Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal.
- RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal; Serviço de Cardiologia, Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal.
Förderung
- AstraZeneca AG
Zitieren
APA
Ferreira, J. P., Vasques-Nóvoa, F., Saraiva, F., Oliveira, A. C., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Diaz, S. O., Santos-Ferreira, D., Friões, F., Goncalves, C., Guimarães, J. T., Leite, M., Marques, P., Mascarenhas, J., Matos, M. I., Pereira, C., …, & Leite-Moreira, A. (2025). Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction. JACC, 86(5), 320-333. https://doi.org/10.1016/j.jacc.2025.05.033
Vancouver
Ferreira JP, Vasques-Nóvoa F, Saraiva F, Oliveira AC, Almeida J, Batista AB, et al. Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction. JACC. 2025;86(5):320-333. doi:10.1016/j.jacc.2025.05.033
BibTeX
@article{Ferreira2025,
author = {Ferreira, João Pedro and Vasques-Nóvoa, Francisco and Saraiva, Francisca and Oliveira, Ana C and Almeida, Jorge and Batista, Ana Beatriz and Barbosa, Arsénio and Ferreira, Ana Filipa and Costa, Cátia and Diaz, Silvia O and Santos-Ferreira, Diogo and Friões, Fernando and Goncalves, Cândida and Guimarães, João Tiago and Leite, Marta and Marques, Pedro and Mascarenhas, Joana and Matos, Maria Inês and Pereira, Catarina and Rodrigues, Pedro and Sharma, Abhinav and Silva, Gualter and Pereira-Sousa, Inês and Sousa, Carla and Zannad, Faiez and Pimenta, Joana and Fontes-Carvalho, Ricardo and Leite-Moreira, Adelino},
title = {Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction},
journal = {JACC},
year = {2025},
volume = {86},
number = {5},
pages = {320--333},
doi = {10.1016/j.jacc.2025.05.033}
}
EUVIMED